HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
BCR
BCR activator of RhoGEF and GTPase
Chromosome 22 · 22q11.23
NCBI Gene: 613Ensembl: ENSG00000186716.22HGNC: HGNC:1014UniProt: P11274
502PubMed Papers
21Diseases
15Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
KinaseOncogene
RESEARCH IMPACT
Highly Studied
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
focal adhesion assemblysmall GTPase-mediated signal transductionkeratinocyte differentiationregulation of Rho protein signal transductionchronic myelogenous leukemiaacute lymphoblastic leukemiacancerneoplasm
✦AI Summary

BCR is a multifunctional regulatory protein with opposing activities toward Rho GTPases, containing three distinct functional domains. Its C-terminal GTPase-activating protein (GAP) domain stimulates GTP hydrolysis by RAC1, RAC2, and CDC42, thereby inactivating these proteins 1. Conversely, its central Dbl homology (DH) domain functions as a guanine nucleotide exchange factor (GEF), promoting conversion of CDC42, RHOA, and RAC1 from GDP-bound to GTP-bound active forms 2. The N-terminal region possesses intrinsic kinase activity 3. BCR serves as a critical negative regulator of neuronal RAC1 activity and regulates macrophage functions including CSF1-directed motility and phagocytosis through RAC1 modulation 1. In keratinocytes, BCR functions primarily as a RHOA GEF, playing a major role in focal adhesion formation and keratinocyte differentiation 2. This dual regulatory capacity allows BCR to fine-tune GTPase signaling across multiple cell types and processes. Clinically, BCR is associated with chr22 myeloid leukemia, though the provided abstracts do not contain specific information regarding BCR's role in this disease or other cancer pathways.

Sources cited
1
BCR GAP domain stimulates GTP hydrolysis by RAC1, RAC2, CDC42; regulates macrophage CSF1-directed motility and phagocytosis through RAC1 modulation
PMID: 17116687
2
BCR DH domain functions as GEF for CDC42, RHOA, and RAC1; plays major role as RHOA GEF in keratinocytes for focal adhesion formation and differentiation
PMID: 23940119
3
BCR N-terminus contains intrinsic kinase activity
PMID: 1657398
⚠Limited data available — This gene has 3 indexed publications. Summary and analysis may be incomplete.
Disease Associationsⓘ21
chronic myelogenous leukemiaOpen Targets
0.82Strong
acute lymphoblastic leukemiaOpen Targets
0.75Strong
cancerOpen Targets
0.62Moderate
neoplasmOpen Targets
0.62Moderate
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveOpen Targets
0.60Moderate
leukemiaOpen Targets
0.57Moderate
gastrointestinal stromal tumorOpen Targets
0.57Moderate
dermatofibrosarcoma protuberansOpen Targets
0.56Moderate
Hypereosinophilic syndromeOpen Targets
0.56Moderate
Myelodysplastic/Myeloproliferative NeoplasmOpen Targets
0.55Moderate
myelodysplastic/myeloproliferative diseaseOpen Targets
0.55Moderate
myeloid leukemiaOpen Targets
0.52Moderate
myelodysplastic syndromeOpen Targets
0.51Moderate
lymphoid leukemiaOpen Targets
0.48Moderate
breast cancerOpen Targets
0.43Moderate
Epiretinal membraneOpen Targets
0.40Weak
pulmonary arterial hypertensionOpen Targets
0.39Weak
acute myeloid leukemiaOpen Targets
0.38Weak
B-cell acute lymphoblastic leukemiaOpen Targets
0.37Weak
Hodgkins lymphomaOpen Targets
0.37Weak
Leukemia, chronic myeloidUniProt
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets15
ASCIMINIBApproved
Bcr/Abl fusion protein inhibitor
chronic myelogenous leukemia
ASCIMINIB HYDROCHLORIDEApproved
Bcr/Abl fusion protein inhibitor
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
BOSUTINIBApproved
Bcr/Abl fusion protein inhibitor
breast cancer
BOSUTINIB MONOHYDRATEApproved
Bcr/Abl fusion protein inhibitor
chronic myelogenous leukemia
DASATINIBApproved
Bcr/Abl fusion protein inhibitor
acute lymphoblastic leukemia
DASATINIB ANHYDROUSApproved
Bcr/Abl fusion protein inhibitor
acute lymphoblastic leukemia
IMATINIBApproved
Bcr/Abl fusion protein inhibitor
IMATINIB MESYLATEApproved
Bcr/Abl fusion protein inhibitor
chronic myelogenous leukemia
NILOTINIBApproved
Tyrosine-protein kinase ABL inhibitor
chronic myelogenous leukemia
NILOTINIB HYDROCHLORIDE MONOHYDRATEApproved
Tyrosine-protein kinase ABL inhibitor
OLVEREMBATINIBPhase III
Bcr/Abl fusion protein inhibitor
PONATINIBApproved
Bcr/Abl fusion protein inhibitor
PONATINIB HYDROCHLORIDEApproved
Bcr/Abl fusion protein inhibitor
chronic myelogenous leukemia
RADOTINIBPhase III
Bcr/Abl fusion protein inhibitor
childhood leukemia
VODOBATINIBPhase II
Tyrosine-protein kinase ABL inhibitor
Parkinson disease
Related Genes
GRB2Protein interaction100%CRKLProtein interaction100%CRKProtein interaction100%PIK3R1Protein interaction100%SHC1Protein interaction100%ABL1Protein interaction97%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
41%
Lung
40%
Liver
33%
Ovary
24%
Heart
23%
Gene Interaction Network
Click a node to explore
BCRGRB2CRKLCRKPIK3R1SHC1ABL1
PROTEIN STRUCTURE
Preparing viewer…
PDB5N7E · 1.65 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.61LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.49 [0.39–0.61]
RankingsWhere BCR stands among ~20K protein-coding genes
  • #530of 20,598
    Most Researched502 · top 5%
  • #131of 1,025
    FDA-Approved Drug Targets12 · top quartile
  • #4,208of 17,882
    Most Constrained (LOEUF)0.61 · top quartile
Genes detectedBCR
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Triple-negative breast cancer molecular subtyping and treatment progress.
PMID: 32517735
Breast Cancer Res · 2020
1.00
2
Choosing the right cell line for breast cancer research.
PMID: 21884641
Breast Cancer Res · 2011
0.90
3
Modifiable risk factors in women at high risk of breast cancer: a systematic review.
PMID: 37095519
Breast Cancer Res · 2023
0.80
4
Symposium Mammographicum 2023.
PMID: 37814292
Breast Cancer Res · 2023
0.72
5
Consistency, now what?
PMID: 28732538
Breast Cancer Res · 2017
0.70